InFlectis BioScience IFB-088 enters phase 1 Clinical Trial
Nantes, France – May 22th, 2018. InFlectis BioScience SAS, a drug discovery company committed to the development of innovative therapeutics […]
Continue Reading
Nantes, France – May 22th, 2018. InFlectis BioScience SAS, a drug discovery company committed to the development of innovative therapeutics […]
Continue ReadingResearchers have found that disease progression in Charcot-Marie-Tooth type 1A (CMT1A) patients reaches a critical point at age 50, after which […]
Continue ReadingDr Shevchuk and his team have established a method that allows them to study the effects of mutations in the […]
Continue ReadingBioPontis Alliance for Rare Diseases today announces receipt of a large three year donation from the prestigious Baillet Latour Fund […]
Continue ReadingImportant implications for experimental trials in Neuromuscular Diseases 9 November 2015 – http://www.ucl.ac.uk/ion/articles/news/20151106 A UCL Institute of Neurology study published […]
Continue ReadingNEW YORK (GenomeWeb) – Through exome sequencing, researchers from Baylor College of Medicine and elsewhere identified apparent causal mutations and […]
Continue ReadingLast Updated: Tuesday 18th August, 2015